Legend Biotech Corp
NASDAQ:LEGN

  • LAST PRICE
    38.2250
  • TODAY'S CHANGE (%)
    -1.6650 (-4.1740%)
  • Bid / Lots
    38.2200/ 15
  • Ask / Lots
    38.2300/ 14
  • Open / Previous Close
    39.8900 / 39.8900
  • Day Range
    38.0200
    39.8900
  • 52 Week Range
    38.0200
    70.1300
  • Volume
    2,162,721

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 13, 2024

  • Nov 12, 2024

      Show headlines and story abstract

    • 7:45AM ET on Tuesday Nov 12, 2024 by MT Newswires
      Companies Mentioned: LEGN
      07:45 AM EST, 11/12/2024 (MT Newswires) -- Legend Biotech (LEGN) reported Q3 loss Tuesday of $0.34 per diluted share, wider than the loss of $0.17 a year earlier. Two analysts surveyed by Capital IQ expected a loss of $0.58. Revenue for the quarter ...

    • 7:01AM ET on Tuesday Nov 12, 2024 by MT Newswires
      Companies Mentioned: HD, MOS, OXY, FLUT, TSN, SE, SPOT, TME, AZN, LEGN, ROIV, ONON, IGT, SHOP, SATS
      07:01 AM EST, 11/12/2024 (MT Newswires) -- US equity markets were trending downward before the open Tuesday after closing at record highs a day earlier as traders assess the waning earnings season. Standard & Poor's 500 futures declined 0.2% in prem...

    • 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
      Companies Mentioned: LEGN

    • 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
      Companies Mentioned: LEGN
      Contract liabilities -- 47,962 Other non-current liabilities 27 56 ------------------ ----------------- Total non-current liabilities 348,824 380,820 ------------------ ----------------- Total liabilities 619,718 597,238 ================== ================= EQUITY Share capital 37 36 Reserves 1,116,070 1,251,335 ------------------ ----------------- Total ordinary shareholders' equity 1,116,107 1,251,371 ------------------ ----------------- Total equity 1,116,107 1,251,371 ================== ================= Total liabilities and equity 1,735,825 1,848,609 ================== ================= LEGEND BIOTECH CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW Three Months Ended Nine Months Ended September 30, September 30, -------------------- ------------------------- -------------------------- US$'000 2024 2023 2024 2023 ---------- ---------- (Unaudited) (Unaudited) (Unaudited) (Unaudited) LOSS BEFORE TAX (120,886) (62,495) (198,644) (373,306) CASH FLOWS USED IN OPERATING ACTIVITIES (75,822) (60,848) (61,955) (297,631) CASH FLOWS PROVIDED BY/(USED IN) INVESTING ACTIVITIES 329,077 (209,072) (762,702) (314,723) CASH FLOWS PROVIDED BY FINANCING ACTIVITIES 4,245 961 6,031 790,565 ---------- ---------- ---------- ---------- NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS 257,500 (268,959) (818,626) 178,211 Effect of foreign exchange rate changes, net 524 (784) 190 (772) Cash and cash equivalents at beginning of the period 201,253 1,233,213 1,277,713 786,031 ---------- ---------- ---------- ---------- CASH AND CASH EQUIVALENTS AT END OF THE PERIOD 459,277 963,470 459,277 963,470 ========== ========== ========== ========== ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS Cash and bank balances 1,217,492 1,242,669 1,217,492 1,242,669 Less: Pledged deposits 583 356 583 356 Time deposits 757,632 278,843 757,632 278,843 ---------- ---------- ---------- ---------- Cash and cash equivalents as stated in the statement of financial position 459,277 963,470 459,277 963,470 ========== ========== ========== ========== Cash and cash equivalents as stated in the statement of cash flows 459,277 963,470 459,277 963,470 ========== ========== ========== ==========

Peers Headlines